UiPath
PATH
$12.76
+3.15%
UiPath, Inc. provides an end-to-end enterprise automation platform, leveraging robotic process automation (RPA), computer vision, and artificial intelligence to automate repetitive tasks across industries. As a pioneer and market leader in the RPA space, UiPath has established a strong competitive identity with its comprehensive platform and extensive partner ecosystem. The current investor narrative centers on UiPath's transition to sustainable profitability, driven by accelerating revenue growth and expanding margins, while debates persist around competitive threats from generative AI and the company's positioning in the emerging agentic AI orchestration market. Recent strong Q1 results and a raised outlook have fueled optimism, but concerns about long-term growth sustainability and valuation remain key discussion points.…
PATH
UiPath
$12.76
Related headlines
Investment Opinion: Should I buy PATH Today?
Rating: Hold. UiPath is a speculative growth stock transitioning to profitability, but the risk-reward is balanced at current levels. The analyst consensus is neutral (no clear recommendation), with an average target price of $13.25, implying 22.2% upside from $10.84. The thesis hinges on whether accelerating revenue growth (17.3% YoY) and improving margins can overcome generative AI disruption fears.
Supporting Evidence: The primary valuation metric is the forward P/E of 12.0x, which is a 66% discount to the software industry average of 35x, suggesting the market is pricing in significant risk. Revenue growth has accelerated from 13.5% in Q2 2026 to 17.3% in Q1 2027, and gross margin remains high at 82.9%. Free cash flow of $375.2M TTM provides a cushion. The implied upside to the average analyst target of $13.25 is 22.2%, but the low target of $10.98 is only 1.3% above the current price, indicating limited downside protection.
Risks & Conditions: The biggest risks are generative AI disruption (which could render RPA obsolete) and competitive pressure from tech giants. This Hold would upgrade to Buy if the stock pulls back below $9.50 (near the 52-week low) or if forward P/E compresses below 10x, providing a wider margin of safety. It would downgrade to Sell if revenue growth decelerates below 10% or if the company reports a net loss again. Overall, UiPath appears fairly valued relative to its growth and profitability trajectory, but the high uncertainty warrants a cautious stance.
Sign up to view all
PATH 12-Month Price Forecast
UiPath presents a mixed picture: accelerating revenue growth and improving profitability are positive, but the stock's persistent downtrend and generative AI risk create significant uncertainty. The forward P/E of 12.0x is attractive relative to the industry, but the low net margin and competitive threats justify the discount. The base case of 15-18% growth and stable margins is most likely, leading to a neutral stance. An upgrade to bullish would require evidence that agentic AI is a net positive for UiPath, while a downgrade to bearish would follow a growth deceleration below 10% or a major competitive disruption.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on UiPath's 12-month outlook, with a consensus price target around $13.25 and implied upside of +3.8% versus the current price.
Average Target
$13.25
0 analysts
Implied Upside
+3.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$11 - $17
Analyst target range
The target price range spans from $10.98 (low) to $17.00 (high), representing a 55% spread between the low and high, indicating high uncertainty about the company's future. The high target of $17.00 assumes successful execution in agentic AI and margin expansion, while the low target of $10.98 prices in competitive pressures from generative AI and potential growth deceleration. The wide spread reflects the binary nature of the investment thesis: either UiPath becomes a key AI orchestration player or faces disruption. With 16 analysts, coverage is adequate for a mid-cap stock, but the lack of a strong consensus suggests investors should conduct independent due diligence.
Bulls vs Bears: PATH Investment Factors
UiPath presents a compelling turnaround story with accelerating revenue growth (17.3% YoY), improving profitability (net income positive for two consecutive quarters), and an attractive forward P/E of 12.0x. However, the stock faces significant headwinds from generative AI disruption risk, a persistent downtrend (-12% over one year), and wide analyst disagreement (55% target spread). The bull case rests on successful execution in agentic AI and continued margin expansion, while the bear case centers on technological obsolescence and competitive threats. The single most important tension is whether UiPath's RPA platform can evolve into an AI orchestration layer or be rendered obsolete by generative AI. Currently, the evidence slightly favors the bull case given the accelerating growth and improving profitability, but the risk of disruption keeps the debate balanced.
Bullish
- Accelerating Revenue Growth: Revenue grew 17.3% YoY in Q1 2027 to $418.4M, accelerating from 15.8% in the prior quarter and 13.5% in Q2 2026, indicating improving demand and successful land-and-expand strategies.
- Transition to Profitability: UiPath achieved net income of $22.5M in Q1 2027 (EPS $0.04) compared to a loss of $22.6M in Q1 2026, demonstrating a clear path to sustainable profitability with operating margin improving to 7.3%.
- Attractive Forward Valuation: With a forward P/E of 12.0x, UiPath trades at a 66% discount to the software industry average of 35x, implying significant earnings growth expectations that are supported by accelerating revenue and margin expansion.
- Strong Free Cash Flow Generation: Trailing twelve-month free cash flow stands at $375.2M, representing a robust FCF margin of ~22%, providing financial flexibility for reinvestment and reducing reliance on external capital.
Bearish
- Generative AI Disruption Risk: Generative AI poses an existential threat to traditional RPA, as large language models can automate tasks without predefined rules, potentially rendering UiPath's core technology obsolete.
- High Valuation Uncertainty: The analyst target spread is 55% ($10.98 low to $17.00 high), reflecting deep disagreement about the company's future, with the stock trading near the low end of the range.
- Persistent Price Downtrend: The stock is down 12% over the past year and 31.7% year-to-date, with a 52-week low of $9.20, indicating sustained selling pressure and lack of institutional conviction.
- Low Net Margin Relative to Peers: Despite improving, net margin of 5.4% in Q1 2027 is well below the software industry average, limiting the company's ability to justify a premium valuation.
PATH Technical Analysis
UiPath is in a sustained downtrend over the past year, with a 1-year price change of -12.0% and a 52-week range of $9.20 to $19.84. The current price of $10.84 sits at just 14.7% of the 52-week range, near the lows, suggesting the stock is deeply oversold and potentially offering a value opportunity, though it could also reflect a falling knife scenario if fundamentals deteriorate further. The stock has underperformed the S&P 500 significantly, with a relative strength of -28.5% over the past year, indicating persistent selling pressure and lack of institutional conviction.
Beta
0.97
0.97x market volatility
Max Drawdown
-51.4%
Largest decline past year
52-Week Range
$9-$20
Price range past year
Annual Return
+8.6%
Cumulative gain past year
| Period | PATH Return | S&P 500 |
|---|---|---|
| 1m | +10.5% | +0.2% |
| 3m | +19.6% | +3.7% |
| 6m | +1.4% | +8.0% |
| 1y | +8.6% | +18.2% |
| ytd | -19.6% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PATH Fundamental Analysis
UiPath's revenue trajectory is accelerating, with Q1 2027 (April 30, 2026) revenue of $418.4 million, up 17.3% year-over-year, compared to 15.8% growth in the prior quarter. The growth is driven by subscription services ($252.9 million) and license revenue ($149.3 million), while professional services contribute a smaller portion. The multi-quarter trend shows consistent acceleration from 13.5% in Q2 2026 to 17.3% in Q1 2027, signaling improving demand and successful land-and-expand strategies. This accelerating growth supports the investment case for a company transitioning from a high-growth to a profitable growth phase.
Quarterly Revenue
$418382000.0B
2026-04
Revenue YoY Growth
+17.3%
YoY Comparison
Gross Margin
81.1%
Latest Quarter
Free Cash Flow
$375234000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PATH Overvalued?
Since net income is positive ($22.5 million in Q1 2027), the trailing P/E ratio of 24.2x is the primary valuation metric. The forward P/E of 12.0x implies the market expects significant earnings growth, with a 50% discount to trailing earnings, reflecting optimism about margin expansion. Compared to the software industry average P/E of approximately 35x, UiPath trades at a 31% discount, which may be justified by its lower net margin (5.4%) versus industry peers, but the accelerating growth and improving profitability could warrant a premium.
PE
24.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 11x~96x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
50.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: UiPath's debt-to-equity ratio is a mere 0.039, indicating minimal leverage, but the company's net margin of 5.4% remains low relative to the software industry average of ~20%, making it vulnerable to margin compression from competitive pricing or cost inflation. Revenue concentration is a concern, as the company relies heavily on subscription services ($252.9M in Q1 2027) and license revenue ($149.3M), with professional services contributing a smaller portion. The current ratio of 2.48 suggests adequate liquidity, but the negative PEG ratio of -0.048 indicates that earnings growth is not expected to keep pace with valuation, raising questions about sustainability.
Market & Competitive Risks: With a beta of 0.974, UiPath has roughly market-level systematic risk, but its 1-year relative strength of -28.5% versus the S&P 500 indicates significant idiosyncratic weakness. The stock trades at a forward P/E of 12.0x, a 66% discount to the software industry average of 35x, which could be a value trap if growth disappoints. Competitive threats from generative AI and large tech players like Nvidia (with its $26B AI investment) could erode UiPath's market position. Regulatory risks are moderate, but the company's exposure to global enterprises makes it sensitive to macroeconomic downturns that could delay automation spending.
Worst-Case Scenario: In a severe downturn where generative AI disrupts RPA demand and growth decelerates below 10%, UiPath's stock could fall to its 52-week low of $9.20, representing a 15.1% decline from the current price of $10.84. If the company fails to achieve profitability consistently and cash burn resumes, the stock could test even lower levels, potentially revisiting the $8 range seen in early 2025. The maximum drawdown of -51.37% from the 52-week high of $19.84 illustrates the stock's volatility, and a repeat of such a decline would imply a price of approximately $5.27, though this is an extreme scenario.
FAQ
The primary risk is generative AI disruption, which could render UiPath's core RPA technology obsolete as large language models automate tasks without predefined rules. Second, competitive pressure from tech giants like Nvidia (with $26B AI investment) and Microsoft could erode market share. Third, the stock's persistent downtrend (-12% over one year, -31.7% YTD) indicates weak institutional support, and the wide analyst target spread (55%) reflects high uncertainty. Fourth, financial risks include low net margin (5.4%) and reliance on subscription revenue growth to sustain valuation. The most severe risk is a growth deceleration below 10%, which could trigger a re-rating to the 52-week low of $9.20 or lower.
The 12-month forecast is balanced across three scenarios. The base case (50% probability) sees revenue growth of 15-18% and stable margins, with the stock trading around the average analyst target of $13.25 (22% upside). The bull case (25% probability) assumes successful agentic AI positioning, driving the stock to $14-$17 (29-57% upside). The bear case (25% probability) involves generative AI disruption and growth deceleration below 10%, pushing the stock to $9.20-$11.00 (down 0-15%). The most likely outcome is the base case, given the accelerating growth trend and improving profitability, but the bear case risk is significant due to technological uncertainty.
Based on forward P/E of 12.0x, UiPath appears undervalued relative to the software industry average of 35x, representing a 66% discount. However, this discount is justified by the company's lower net margin (5.4% vs. industry ~20%) and the existential threat from generative AI. The trailing P/E of 24.2x is more in line with historical software valuations but still below the industry average. The market is pricing in significant risk, implying that investors expect either strong earnings growth or a disruptive event. Compared to its own history, the stock trades near the bottom of its 52-week range (14.7% of the range), suggesting it is undervalued relative to recent levels, but the downtrend indicates persistent selling pressure.
UiPath is a high-risk, high-reward investment. The stock offers 22.2% upside to the average analyst target of $13.25, but the wide target spread (55% from low to high) indicates significant uncertainty. The forward P/E of 12.0x is attractive relative to the software industry average of 35x, but the low net margin of 5.4% and generative AI disruption risk justify the discount. For growth investors with a 2-3 year horizon and tolerance for volatility, PATH could be a good buy if you believe in the agentic AI thesis. However, for conservative investors, the risk of permanent capital loss is too high. A better entry point would be below $9.50, near the 52-week low.
UiPath is better suited for long-term investment (2-3 years minimum) due to its speculative nature and high volatility (beta 0.974, max drawdown -51.37%). Short-term trading is risky given the persistent downtrend and lack of positive momentum. The stock's transition to profitability and potential in agentic AI are long-term themes that require patience. The company does not pay a dividend, so total return depends on price appreciation. For long-term investors, the current valuation (forward P/E 12.0x) provides a margin of safety if the company executes, but the risk of disruption means position sizing should be conservative. A minimum holding period of 2 years is recommended to allow the agentic AI thesis to play out.